Because idelalisib mitigates the BCR nexus, we hypothesized that microenvironment-induced resistance to bendamustine cell death of CLL lymphocyte may be abrogated with idelalisib addition. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.